According to Andrew Gengos, president and CEO of Neuraltus, the company’s experimental drug is designed to flip a molecular switch in cells known as macrophages in the blood and microglia in the central nervous system.

“There’s a switch that it hits,” Gengos said, “that regulates these cells from an activated, inflammatory mode back to a more normal, wound-healing mode.” (For more about this phenomenon, see ALS: Not Just About Motor Neurons Anymore, in the May-June 2010 ALS Newsmagazine.)

Testing in ALS research mice has shown NP001 flips a molecular switch, turning certain immune system cells from damaging to protective.

Neuraltus is completing its mouse studies, and hopes to conduct a phase 1 safety trial of NP001 in people with ALS by fall 2010.

See the full article here.

Related posts:

1. New Stem Cell Breakthroughs Dr. Jon LaPook Looks At Advances In Stem Cell Research...
2. Young ALS Patients Come Together to End ALS with New National Campaign The ALS Therapy Development Institute (ALS TDI) announced today that...
3. Tim’s Speech from the Often Awesome Benefit Show (5/18/2010) Almost a year ago we met here. It was the...
4. “I’m Jim Cotter, and I’m dying of ALS.’’ Boston Globe story on the book about Jim Cotter, BC...
5. The EyeWriter – TEMPT One, legendary LA graffiti writer and ALS sufferer “Art is a tool of empowerment and social change, and...

Related posts brought to you by Yet Another Related Posts Plugin.